ALSPW Spineway SAS

SPINEWAY : Great success at the 24th AMCICO Congress in Mexico

SPINEWAY : Great success at the 24th AMCICO Congress in Mexico

Press release        

Ecully, September 12, 2024 – 6 p.m.



SPINEWAY

Great success at the 24th AMCICO Congress in Mexico

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 24th (Asociación Mexicana de Cirujanos de Columna) congress in Cancún from September 4 to 8, 2024.

This annual congress of spine surgeons is a flagship event for the spine surgery sector in Mexico, the largest market in Central and Latin America.

In partnership with the MAVA Group, a major player in the distribution of orthopedic and spinal implants in Mexico, the Spineway Group, which presented its range of ESP cervical and lumbar prostheses, organized a special “Meet the Expert” session during the congress.

Held in the main auditorium of the congress, the Meet the Expert event was a great success, with over 100 surgeons taking part. Professor Jean-Yves Lazennec (Hôpital Pitié-Salpêtrière/AP-HP), designer of the ESP prosthesis and internationally recognized for his expertise in spinal arthroplasty, presented the concepts and benefits of ESP prostheses for cervical and lumbar surgery.

     

This exposure among key opinion leaders (KOLs) is expected to promote the use of ESP disc prostheses in Latin America, an established market for the Group, in 2025. In addition, Latin American surgeons will be taking part in the next session of hands-on workshops scheduled for early November at the IRCAD Institute in Strasbourg (France).

Following on from the SILACO Latin American, Spanish and Portuguese Orthopedic Surgery Association congress in Mexico City in July 2024, this new congress in Mexico will enable Spineway to increase its visibility and reputation in Latin America. This positions Spineway as a key player in the sector and reinforce its aim of becoming a major player in less invasive spine treatments.

Next event:

September 23, 2024 – H1 2024 results

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:





SPINEWAY



Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060
 



AELIUM



Investor relations

Solène Kennis

        

Attachment



EN
12/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : H1 2025 results - Continued improvement in results and fina...

Spineway : H1 2025 results - Continued improvement in results and financial position Press release         Ecully, July 30, 2025 – 7 p.m.   SPINEWAY H1 2025 results  Continued improvement in results and financial positionFull-year 2025 growth target confirmed In thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535Cost of sales(1,702)(2,059)Gross margin% of revenue3,87069%4,47668%Net operating expensesOf which general operating costs(5,068)(2,086)(5,246)(2,232)Of which personnel expenses(2,374)(2,685)Operating income/(loss)(1,197)(770)Fina...

 PRESS RELEASE

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration de...

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration des résultats et de la situation financière Communiqué de presse        Ecully, le 30 juillet 2025 –19h SPINEWAY Résultats semestriels 2025 Poursuite de l’amélioration des résultats et de la situation financièreObjectif de croissance confirmé pour l’année 2025 En milliers d'eurosComptes consolidés – Non auditésS1 2025S1 2024Chiffre d'affaires5 5736 535Coût des ventes- 1 702- 2 059Marge brute% du CA3 87069%4 47668%Coûts nets d’exploitationDont coûts de fonctionnement- 5 068- 2 086- 5 246- 2 232Dont charges de personnel-...

 PRESS RELEASE

Spineway : GMED approval for new production line dedicated to ESP pros...

Spineway : GMED approval for new production line dedicated to ESP prostheses - First production of LP-ESP intervertebral disc prostheses Press release         Ecully, July 3, 2025 – 6:30 p.m. SPINEWAY GMED approval for new production line dedicated to ESP prostheses First production of LP-ESP intervertebral disc prostheses Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral di...

 PRESS RELEASE

SPINEWAY : Approbation du GMED pour la nouvelle ligne de production dé...

SPINEWAY : Approbation du GMED pour la nouvelle ligne de production dédiée aux prothèses ESP - 1ère production de prothèses de disque intervertébral LP-ESP Communiqué de presse          Ecully, le 3 juillet 2025 – 18h30 SPINEWAY Approbation du GMED pour la nouvelle ligne de production dédiée aux prothèses ESP 1ère production de prothèses de disque intervertébral LP-ESP Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que sa filiale Spine Innovations a reçu la validation du (Organisme notifié français) ...

 PRESS RELEASE

Spineway : Minutes of the General Meeting of June 4, 2025

Spineway : Minutes of the General Meeting of June 4, 2025 Press release         Ecully, June 6, 2025 – 6.00 p.m.   SPINEWAY Minutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2025. The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch